UChicago Medicine's current clinic on Salt Creek Lane in Hinsdale will close Nov. 21, and open across the street in a new, larger facility Dec. 2.
Alyssa Stolarik, RN, BSN, clinical coordinator of Cardiology at Hackensack Meridian Health Mountainside Medical Center, received the Second Best Research Poster Award at the American College of Cardiology (ACC) Quality Summit held in San Antonio, Texas. Her work, titled “Improving Compliance with Post-PCI Creatinine,” highlights significant advancements in the management of post-procedural care and patient outcomes. The research addresses the critical issue of acute kidney injury (AKI) post-percutaneous coronary intervention (PCI), demonstrating a marked reduction in risk-standardized AKI rates, which significantly surpasses national benchmarks.
Jiang He, M.D., Ph.D., Professor and Chair Designate of Epidemiology in the Peter O’Donnell Jr. School of Public Health at UT Southwestern Medical Center, is a 2024 recipient of the American Heart Association’s (AHA) highest commendation, the Distinguished Scientist award. The honor recognizes Dr. He’s prolific research on reducing the risks of cardiometabolic diseases, including heart disease, stroke, obesity, Type 2 diabetes, hypertension, dyslipidemia, and chronic kidney disease.
Researchers from both Johns Hopkins Medicine and Yale University collaborated on the development and application of a diagnostic model to detect acute interstitial nephritis (AIN) in patients, which could have a lasting impact on getting patients diagnosed earlier
The article, Safety of Kidney Transplantation from Donors with HIV, details findings supporting HIV-to-HIV kidney transplants as safe and just as effective as those using organs from donors without HIV.
In patients with chronic kidney disease, the loss of podocytes—part of the kidney’s glomerular filtration barrier—causes irreversible disease progression. So far, physicians and researchers have found no way to effectively prevent podocyte damage, loss, and deterioration leading to end-stage kidney disease.
Most small kidney stones can pass on their own. However, kidney stones that are too large to pass on their own or cause bleeding, kidney damage or ongoing urinary tract infections may require surgical treatment. Dr. Aaron Potretzke, a Mayo Clinic urologist in Rochester, Minnesota, explains some of the different surgical options for removing kidney stones.
A maioria dos cálculos renais podem ser expelidos por conta própria. "No entanto, os cálculos renais que são grandes demais para serem expelidos sozinhos ou que causam sangramento, danos nos rins ou infecções urinárias recorrentes podem exigir tratamento cirúrgico." O Dr. Aaron Potretzke, urologista da Mayo Clinic em Rochester, Minnesota, explica algumas das opções cirúrgicas para remover os cálculos renais.
La mayoría de los cálculos renales pueden ser expulsados por su cuenta. "Sin embargo, los cálculos renales que son demasiado grandes para ser expulsados por sí solos o que causan sangrado, daño renal o infecciones urinarias recurrentes pueden requerir tratamiento quirúrgico." El Dr. Aaron Potretzke, urólogo en Mayo Clinic en Rochester, Minnesota, explica algunas de las opciones quirúrgicas para extirpar los cálculos renales.
يُمكن لمعظم حصوات الكلى الصغيرة أن تمُر بشكل طبيعي. ومع ذلك، فإن حصوات الكلى الكبيرة جدًا التي لا يمكنها الخروج من تلقاء نفسها أو تسبب النزيف أو تلف الكلى أو التهابات الجهاز البولي المستمرة قد تتطلب تدخلاً جراحيًا. يشرح الدكتور آرون بوترتزكي، أخصائي المسالك البولية في مايو كلينيك بروتشستر، مينيسوتا، بعض الخيارات الجراحية لإزالة حصوات الكلى.
Findings from Rutgers Health and other researchers may lead to more precise treatment.
Kidney Week 2024: Live Event
The National Institutes of Health awarded a four-year, $2.6 million grant to researchers at Case Western Reserve University to study how high blood-pressure drugs affect patients with chronic kidney disease (CKD).
Dr. Roy-Chaudhury will head up an organization—with nearly 21,000 health professionals representing 140 countries—dedicated to leading the fight against kidney diseases.
Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients’ kidney function in a phase 2 trial. Investigators now have data from a phase 3 trial with clazakizumab. The findings from the Phase 3 IMAGINE trial, the largest placebo-controlled study in kidney transplant recipients with caAMR, will be presented at ASN Kidney Week 2024 October 23– 27.
IgA nephropathy is an autoimmune kidney disease, and complement, a component of the innate immune system, plays a role in the condition’s pathogenesis. Investigators have developed and tested a novel gene therapy that enters kidney cells and enables them to block complement activation. The research will be presented at ASN Kidney Week 2024 October 23– 27.
For kidney transplant recipients experiencing antibody-mediated rejection, the current standard of care involves removing donor-specific antibodies (DSAs) through plasmapheresis (PLEX)—a procedure that removes antibodies from the plasma portion of the blood. Results from a recent clinical trial reveal that an investigational drug called imlifidase, which cleaves and inactivates the type of antibodies that include DSAs, is more effective than PLEX. The research will be presented at ASN Kidney Week 2024 October 23–27.
The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23–27.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
